Who answers for a trial, and what they have to keep

A study is not a thing that happens, it is a thing people are responsible for

A registry record makes a trial look like an event. Somebody started it, subjects joined it, and eventually numbers came out.

The regulations describe something else. They describe two named parties, each carrying a list of duties, and a chain of paper connecting them.

One party is the sponsor, meaning whoever takes on the investigation. The other is the investigator, meaning the person under whose direction the drug is given.

The word sponsor is a false friend on a page like this. Elsewhere it means whoever paid for a study, which is a question about bias rather than about duties.

The sponsor duty list, in one sentence

The subpart opens with a single sentence that names five general responsibilities, and every later section is a detail of one of them.

Sponsors are responsible for selecting qualified investigators and for providing them with the information they need to conduct an investigation properly.

They are responsible for ensuring proper monitoring, and for ensuring the investigation is conducted in accordance with the general plan and protocols in the application.

They are responsible for maintaining an effective application. And they are responsible for ensuring that the agency and all participating investigators are promptly informed of significant new adverse effects or risks.

That last clause is the one to hold on to. Informing everyone quickly is not a courtesy in this system, it is a listed responsibility.

Choosing an investigator, and the statement that person signs

The selection rule is short and its adjective is doing the work. A sponsor shall select only investigators qualified by training and experience as appropriate experts to investigate the drug.

Before permitting anyone to begin, the sponsor has to obtain a signed investigator statement, and the rule lists what the statement contains.

It names the investigator and address, the protocols, any medical school or hospital or research facility involved, any clinical laboratory facilities, and the review board responsible for the study.

It then carries a set of commitments from the investigator personally. To follow the current protocol and change it only after notifying the sponsor, except where needed to protect a subject.

To comply with the obligations of clinical investigators. To personally conduct or supervise the investigation. To inform potential subjects that the drugs are being used for investigational purposes.

To ensure the consent and review board requirements are met. To report adverse experiences to the sponsor. To have read and understood the investigator brochure, including potential risks and side effects.

And to ensure that associates, colleagues and employees assisting are informed about their obligations in meeting those commitments. A list of the subinvestigators goes in as well.

Two more items follow the statement. A curriculum vitae or other statement of qualifications showing what makes the person an expert, and a clinical protocol appropriate to the phase.

The money question is asked in advance

The same section requires financial disclosure information, and it is collected before the work starts rather than argued about afterwards.

The sponsor obtains sufficient accurate financial information to allow complete and accurate certification or disclosure statements under the financial disclosure part.

It also obtains a commitment from the investigator to promptly update that information if anything relevant changes during the study.

The obligation does not end at the last visit. It runs for one year following the completion of the study, which is a longer window than most disclosures anywhere else.

A monitor is chosen on the same principle as an investigator. The sponsor selects a monitor qualified by training and experience to monitor the progress of the investigation.

The drug only moves between named people

Three separate sections build a single rule about custody, and read together they close the circle.

The sponsor shall ship investigational new drugs only to investigators participating in the investigation. That is the outbound limit, and it has no exception clause.

The investigator administers the drug only to subjects under the investigator's personal supervision, or under a subinvestigator responsible to the investigator. The investigator shall not supply the drug to any person not authorized to receive it.

Material arriving from abroad is fenced the same way. An investigational drug offered for import complies where the consignee is the sponsor, or a qualified investigator named in the application, or an identified domestic agent of a foreign sponsor.

So at every step the rule asks who this named person is. There is no point in that chain where the material is simply available.

Keeping the investigators informed

Before the investigation begins, a sponsor gives each participating clinical investigator an investigator brochure, and the contents of that document are specified elsewhere in the part.

The duty then continues for the life of the study. The sponsor keeps each participating investigator informed of new observations discovered by or reported to the sponsor.

The rule singles out what those observations are about. Adverse effects and safe use are named specifically.

The delivery method is left open. Periodically revised brochures, reprints or published studies, reports or letters to investigators, or other appropriate means all qualify.

Important safety information has its own channel, and the rule points at the safety reporting section for it. A companion article walks through that section.

What happens when something is going wrong

The review section is where the duties turn into consequences, and it contains two of the sharpest provisions in the subpart.

A sponsor who discovers that an investigator is not complying with the signed agreement, the general plan, or the requirements of the part shall promptly do one of two things.

Either secure compliance, or discontinue shipments of the drug to that investigator and end the investigator's participation. If participation ends, the investigator must dispose of or return the drug, and the agency is notified.

The second provision is about the drug rather than the person. A sponsor who determines that its investigational drug presents an unreasonable and significant risk to subjects shall discontinue the investigations that present the risk.

Then a notification list. The agency, all review boards, and all investigators who have at any time participated in the investigation.

And a deadline attached to a judgment. The sponsor shall discontinue as soon as possible, and in no event later than five working days after making the determination.

The records on both sides

The sponsor maintains adequate records showing the receipt, shipment or other disposition of the investigational drug, with the investigator name, the date, the quantity and the batch or code mark.

It also maintains complete and accurate records of the financial interests paid to clinical investigators, and of the other financial interests covered by the disclosure part.

Retention runs for two years after a marketing application is approved. Where no approval follows, it runs until two years after shipment and delivery for investigational use is discontinued and the agency has been notified.

The investigator keeps a mirror set. Adequate records of the disposition of the drug, including dates, quantity and use by subjects, and case histories on each individual.

Case histories are defined generously. Case report forms and supporting data, signed and dated consent forms, and medical records such as progress notes, hospital charts and nurses' notes.

One sentence in that paragraph is a quiet audit rule. The case history for each individual shall document that informed consent was obtained prior to participation in the study.

Investigator retention matches the sponsor's at two years, measured from approval for the indication investigated, or from the discontinuation of the investigation where no application follows.

Reporting up, and the file the agency can open

The investigator furnishes all reports to the sponsor, who is responsible for collecting and evaluating the results obtained.

The safety duty is immediate and deliberately wide. An investigator must immediately report to the sponsor any serious adverse event, whether or not considered drug related.

That includes events already listed in the protocol or the investigator brochure, and the report must include an assessment of whether there is a reasonable possibility that the drug caused the event.

A final report goes to the sponsor shortly after the investigator's participation ends, and the financial information is updated on the same one-year tail described earlier.

The agency can then read the file. On request from a properly authorized officer or employee, at reasonable times, the investigator permits access to copy and verify records and reports.

One limit is written into the same sentence. The investigator is not required to divulge subject names unless particular records need more detailed study, or unless there is reason to believe they do not represent actual case studies or actual results obtained.

The sanction at the end of the list

The last section of the subpart deals with an investigator who has broken the arrangement, and its trigger phrase is precise.

It applies where an investigator has repeatedly or deliberately failed to comply with the requirements of this part or the consent and review board parts. It also applies to repeatedly or deliberately submitting false information in a required report.

The first step is a written notice of the matter complained of, and an opportunity to explain in writing or at the investigator's option in an informal conference. An accepted explanation ends the proceeding.

If it is not accepted, a regulatory hearing follows on whether the investigator is eligible to receive test articles and to conduct investigations supporting an application.

A finding of ineligibility reaches a long way. The notice explains that the person becomes ineligible across drugs, biologics, devices, new animal drugs, foods bearing a nutrient content or health claim, infant formulas, food and color additives, and tobacco products.

The data is then examined rather than automatically discarded, to determine whether unreliable data essential to an investigation or to an approval was submitted.

Reinstatement is possible on adequate assurances about future conduct. The section is a professional sanction with a route back, not a permanent expulsion.

What a reader can do with a duty list that does not reach a website

The scope has to be said again, because it decides what these sections are worth here. The applicability section opens: "Except as provided in this section, this part applies to all clinical investigations of products". It then names them: those "subject to section 505 of the Federal Food, Drug, and Cosmetic Act or to the licensing provisions of the Public Health Service Act".

A company that has filed nothing is neither a sponsor nor an investigator in that sense, so none of this is a duty it is failing. It is a description of the regulated version of the same activity.

What it gives a reader is a picture of what answerable looks like. A named expert who signed a list of commitments, a monitor, a brochure, and a chain of shipment records.

It also gives a set of questions with checkable answers. When a page cites a study, the registration record names a responsible party, and a companion article covers what that record has to hold.

And it explains why so little exists to read in this market. Duty lists produce documents, and where nobody carries the duties, the documents were never created in the first place.

Sources

Each document below is named as it names itself, with the date printed on that document rather than the day it was read.

1. 21 CFR 312.50 — General responsibilities of sponsors, the single sentence naming selection, information, monitoring, conduct in accordance with the plan, maintaining an effective application, and prompt notification of new adverse effects or risks — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
2. 21 CFR 312.53 — Selecting investigators and monitors, including the expert qualification standard, the ship-only-to-participating-investigators rule, the contents of the signed investigator statement, the curriculum vitae and protocol requirements, and the financial disclosure obligation with its one-year tail — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
3. 21 CFR 312.55 — Informing investigators, requiring an investigator brochure before the investigation begins and continuing updates on new observations, particularly adverse effects and safe use — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
4. 21 CFR 312.56 — Review of ongoing investigations, including the secure-compliance-or-discontinue-shipments duty on discovering noncompliance and the five working day limit on discontinuing an investigation that presents an unreasonable and significant risk — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
5. 21 CFR 312.57 — Recordkeeping and record retention for sponsors, covering receipt, shipment and disposition records, financial interest records, and the two-year retention periods — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
6. 21 CFR 312.59 — Disposition of unused supply of investigational drug, requiring return from each investigator whose participation ends and permitting alternative disposition only where humans are not exposed to risks — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
7. 21 CFR 312.61 — Control of the investigational drug, limiting administration to subjects under the investigator's personal supervision and barring supply to any person not authorized to receive it — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
8. 21 CFR 312.62 — Investigator recordkeeping and record retention, including drug disposition records, the definition of case histories, the requirement that each case history document consent obtained prior to participation, and the two-year retention period — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
9. 21 CFR 312.64 — Investigator reports, including the duty to immediately report any serious adverse event whether or not considered drug related with an assessment of reasonable possibility, the final report, and financial disclosure updates — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
10. 21 CFR 312.68 — Inspection of investigator's records and reports, granting agency access to copy and verify records while limiting the disclosure of subject names to defined circumstances — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
11. 21 CFR 312.70 — Disqualification of a clinical investigator, including the repeatedly or deliberately standard, the notice and hearing procedure, the categories of test articles a finding of ineligibility reaches, the examination of submitted data, and reinstatement — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
12. 21 CFR 312.110 — Import and export requirements, whose import paragraph limits the United States consignee to the sponsor, a qualified investigator named in the application, or an identified domestic agent of a foreign sponsor — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026
13. 21 CFR 312.2 — Applicability, whose opening sentence states that except as provided in that section the part applies to all clinical investigations of products subject to the approval provisions of the drug law or the licensing provisions of the public health law — Office of the Federal Register, Electronic Code of Federal Regulations, August 2026